Avtor/Urednik		Bren, A; Kandus, A; Varl, J; Ponikvar, R; Kveder, R; Buturović, J
Naslov		Safety of epoetin omega vs epoetin alfa in hemodialysis patients
Tip		članek
Vir		In: Boletis JN, Iatrou C, Siakotos M, et al, editors. BANTAO. Proceedings of the 5th congress of the Balkan cities association of nephrology dialysis, transplantation and artificial organs; 2001 Sep30-Ovt 3; Thessaloniki. Thessaloniki: Hellenic society of nephrology,
Leto izdaje		2001
Obseg		str. 154-5
Jezik		eng
Abstrakt		The aim of our study was to evaluate and compare the safety and patient comfort of epoetin omega and epoetin given subcutaneously in chronic hemodialysis patients for a period of 24 weeks. When treated with epoetin omega, only one patient gave a rating of mild pain, and when treated with epoetin alfa, only 6 patients described a mild pain. A hematoma was observed in one patient at the site of epoetin omega injection, and in two patients after an epoetin alfa injection. Local erythema (1cm diameter) appered in one patient after an epoetin omega injection. Thromboses of vascular access occurred in three patients during an epoetin omega treatment (Hgb ranged 10.2-11.7 g/dL), and in three patients during epoetin alfa treatment (Hgb ranged 9.8-12.5 g/dL). Mean systolic pre-dialysis blood pressure was 148 +- 16 mm Hg during an epoetin omega treatment period, and 146 +- 17 mm Hg during an epoetin alfa treatment period, and diastolic pressure 84 +- 9 and 83 +- 8 mm Hg, respectively (NS). Mean body weight at the end of dialysis was 67 +- 13 kg during an epoetin omega treatment, and 68 +- 13 kg during an epoetin alfa treatment (NS). In conclusion, no serious side effect of either epoetin group were noted during this study.
Deskriptorji		KIDNEY FAILURE, CHRONIC HEMODIALYSIS EPOETIN ALFA ANEMIA HEMOGLOBINS BLOOD PRESSURE PROSPECTIVE STUDIES FERRITIN